Put companies on watchlist
SÜSS MicroTec SE
ISIN: DE000A1K0235
WKN: A1K023
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

SÜSS MicroTec SE · ISIN: DE000A1K0235 · EQS - adhoc news (80 News)
Country: Germany · Primary market: Germany · EQS NID: 1514651
15 December 2022 06:27PM

SÜSS MicroTec SE: Dr. Goetz M. Bendele will not return to the Management Board of SÜSS MicroTec SE | Dr. Bernd Schulte remains in office as Chief Executive Officer (CEO)


EQS-Ad-hoc: SÜSS MicroTec SE / Key word(s): Personnel
SÜSS MicroTec SE: Dr. Goetz M. Bendele will not return to the Management Board of SÜSS MicroTec SE | Dr. Bernd Schulte remains in office as Chief Executive Officer (CEO)

15-Dec-2022 / 18:27 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Dr. Goetz M. Bendele will not return to the Management Board of SÜSS MicroTec SE | Dr. Bernd Schulte remains in office as Chief Executive Officer (CEO)

Garching, Germany, 12/15/2022 - For personal reasons and by mutual agreement with the Supervisory Board of SÜSS MicroTec SE, Dr. Goetz M. Bendele will not be reappointed as a member of the Management Board and Chief Executive Officer of SÜSS MicroTec SE. Dr. Bendele is thus leaving the Company. The Supervisory Board regrets Dr. Bendele's departure and thanks him for his achievements since taking office.

The office of Chief Executive Officer (CEO) will continue to be held by Dr. Bernd Schulte, who was delegated to the Management Board from the Supervisory Board in October in order to temporarily replace Dr. Bendele. Dr. Schulte has agreed to take over as Chief Executive Officer until the end of the delegation period, which is not to last more than one year. He will return to the Supervisory Board in October 2023 at the latest. The Supervisory Board has initiated a process to permanently fill the third Management Board position following the departure of Dr. Bendele next year.


Contact:

SÜSS MicroTec SE
Franka Schielke
Investor Relations
Schleissheimer Strasse 90
85748 Garching, Germany
Tel.: +49 (0)89 32007-161
Email: franka.schielke@suss.com

15-Dec-2022 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: SÜSS MicroTec SE
Schleissheimer Strasse 90
85748 Garching
Germany
Phone: +49 (0)89 32007-161
Fax: +49 (0)89 4444 33420
E-mail: franka.schielke@suss.com
Internet: www.suss.com
ISIN: DE000A1K0235
WKN: A1K023
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1514651

 
End of Announcement EQS News Service

1514651  15-Dec-2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1514651&application_name=news&site_id=boersengefluester_html
Visual performance / price development - SÜSS MicroTec SE
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.